Mesoblast reaches 300-patient enrollment in back pain trial
NEW YORK - Mesoblast Limited (NASDAQ:MESO; ASX:MSB) announced Monday that it has enrolled at least 300 patients in its Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Shares rose over 13% in the past week to $16.22, reflecting investor optimism about the trial milestone.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
NEW YORK - Mesoblast Limited (NASDAQ:MESO; ASX:MSB) announced Monday that it has enrolled at least 300 patients in its Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Shares rose over 13% in the past week to $16.22, reflecting investor optimism about the trial milestone. The MSB-DR004 trial is a randomized, placebo-controlled study testing a single intra-discal injection of rexlemestrocel-L. The trial’s primary endpoint measures reduction of low back pain at 12 months compared to sham controls.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- NEW YORK - Mesoblast Limited (NASDAQ:MESO; ASX:MSB) announced Monday that it has enrolled at least 300 patients in its Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Shares rose over 13% in the past week to $16.22, reflecting investor optimism about the trial milestone.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 6m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Mesoblast reaches 300-patient enrollment in back pain trial
Sources1TypeCoverageInvesting.com · Company News